APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION FOR THE USE OF RENUVION IN DERMAL RESURFACING PROCEDURESBy ApyxMedical|2025-12-12T19:32:06-05:00June 1, 2021|2021 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND UPDATES FULL YEAR 2021 OUTLOOKBy ApyxMedical|2025-12-12T19:32:32-05:00May 12, 2021|2021 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO RELEASE FIRST QUARTER OF FISCAL YEAR 2021 FINANCIAL RESULTS ON MAY 12, 2021By ApyxMedical|2025-12-12T19:32:54-05:00April 12, 2021|2021 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS; INTRODUCES FULL YEAR 2021 FINANCIAL OUTLOOKBy ApyxMedical|2025-12-12T19:33:27-05:00March 31, 2021|2021 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2020 FINANCIAL RESULTS ON MARCH 31, 2021By ApyxMedical|2025-12-12T19:33:50-05:00February 1, 2021|2021 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION REPORTS PRELIMINARY FULL YEAR AND FOURTH QUARTER 2020 REVENUE RESULTSBy ApyxMedical|2025-12-12T19:34:13-05:00January 13, 2021|2021 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO PARTICIPATE IN THE ICR CONFERENCE 2021By ApyxMedical|2025-12-12T19:34:37-05:00January 5, 2021|2021 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION ANNOUNCES APPROVAL FROM FDA TO BEGIN PHASE II OF U.S. IDE STUDYBy ApyxMedical|2025-12-12T19:34:58-05:00November 23, 2020|2020 Shareholder News, Case Study, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION REPORTS THIRD QUARTER 2020 FINANCIAL RESULTSBy ApyxMedical|2025-12-12T19:35:21-05:00November 9, 2020|2020 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION ANNOUNCES UPDATES ON U.S. IDE CLINICAL STUDIESBy ApyxMedical|2025-12-12T19:35:52-05:00November 9, 2020|2020 Shareholder News, Case Study, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION ANNOUNCES TWO PEER-REVIEWED CLINICAL PUBLICATIONS EVALUATING RENUVION’S HELIUM PLASMA TECHNOLOGYBy ApyxMedical|2025-12-12T19:36:16-05:00October 20, 2020|2020 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO RELEASE THIRD QUARTER OF FISCAL YEAR 2020 FINANCIAL RESULTS ON NOVEMBER 9, 2020By ApyxMedical|2025-12-12T19:36:39-05:00October 1, 2020|2020 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN SEPTEMBERBy ApyxMedical|2025-12-12T19:37:13-05:00August 31, 2020|2020 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION REPORTS SECOND QUARTER 2020 FINANCIAL RESULTSBy ApyxMedical|2025-12-12T19:37:38-05:00August 7, 2020|2020 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION TO RELEASE SECOND QUARTER OF FISCAL YEAR 2020 FINANCIAL RESULTS ON AUGUST 10, 2020By ApyxMedical|2025-12-12T19:37:59-05:00June 25, 2020|2020 Shareholder News, J-Plasma, Renuvion|
APYX MEDICAL CORPORATION ANNOUNCES REGULATORY CLEARANCE TO MARKET AND SELL ITS HELIUM PLASMA TECHNOLOGY PRODUCTS IN FIVE NEW COUNTRIESBy ApyxMedical|2025-12-12T19:38:21-05:00June 22, 2020|2020 Shareholder News, J-Plasma, Renuvion|
